BofA analyst Alec Stranahan raised the firm’s price target on Crispr Therapeutics (CRSP) to $86 from $85 and keeps a Buy rating on the shares. With sufficient cash to support “years of development in the pipeline,” the firm remains positive on the Crispr story and the potential value coming from the pipeline, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Cathie Wood’s ARK Investment buys 187K shares of Crispr Therapeutics today
- Crispr Therapeutics management to meet with Truist
- Crispr Therapeutics initiated with a Buy at H.C. Wainwright
- Vertex Pharmaceuticals (VRTX) Set for Painless Gains After FDA Approval
- Crispr Therapeutics price target lowered to $30 from $45 at Morgan Stanley